You may be searching for a peptide to calm inflammation after an injury, or the low-grade kind that comes with excess weight. Those are different problems. The honest answer is that only one peptide has strong human data on an inflammation marker, and it was not tested for that purpose.
This guide takes each peptide in turn. For each one, you get the kind of evidence behind it: people, animals or cells.
| Peptide | Best evidence on inflammation | Can it be prescribed? |
|---|---|---|
| Semaglutide | Randomized trials in people (CRP) | Yes, FDA-approved |
| GHK-Cu | Cells and mice | Compoundable except by injection |
| Glutathione | One small trial in people, not significant | Compoundable |
| BPC-157 | Animals only | No: on no FDA compounding list |
Semaglutide: the one with human numbers
Semaglutide is a weight-loss medicine, not an anti-inflammatory. Still, one of its trials made an inflammation marker a formal endpoint. That marker is C-reactive protein, or CRP, a blood protein that rises with inflammation.
The trial enrolled 529 adults with a body mass index of 30 or higher and heart failure with preserved ejection fraction [1]. They took semaglutide 2.4 mg or placebo once a week for 52 weeks.
−43.5%
change in CRP on semaglutide 2.4 mg weekly over 52 weeks
Kosiborod 2023
−7.3%
change in CRP on placebo over the same 52 weeks
Kosiborod 2023
0.61
estimated treatment ratio for CRP (95% CI 0.51 to 0.72)
Kosiborod 2023
A pooled analysis then combined this trial with a second one in people who also had type 2 diabetes [2]. Of 1,145 patients, 71% had a CRP of 2 mg/L or higher at the start. Semaglutide lowered CRP more than placebo at every starting level.
One finding stands out if you wonder whether this is just weight loss. The fall in CRP was similar no matter how much weight people lost [2]. That hints at an effect beyond the scale. It does not prove one, and these results apply to people like those enrolled.
If weight is part of your picture, the weight-loss peptide board ranks who prescribes it.
What semaglutide itself does to the gut and the pancreas in trials is covered in semaglutide side effects.
GHK-Cu: promising in cells, untested in people
GHK-Cu is a small copper-binding peptide found naturally in human blood. A 2015 review describes it drawing immune cells to wounds and speeding skin repair in animals [3]. The same review notes it has been proposed for skin inflammation. Proposed is not tested.
The clearest inflammation data come from one 2016 study in mouse immune cells and in mice [4]. After exposure to a bacterial toxin, GHK-Cu lowered two inflammatory signals, TNF-α and IL-6. It also reduced lung damage and the flood of inflammatory cells into the lungs.
That is a lung-injury model in mice. It tells you nothing yet about joint pain or sore muscles in people. The injected form is also on no compounding list, which matters for what you can be prescribed. The difference between routes is covered in GHK-Cu topical vs injected.
Glutathione: one small, inconclusive trial
Glutathione is an antioxidant your body makes, and it is often sold as an anti-inflammatory. The human evidence on inflammation markers is thin.
In one randomized trial, 40 people with mild to moderate acne took 500 mg of oral glutathione or placebo daily for 4 weeks [5]. The inflammatory marker IL-1α fell in the glutathione group. The change was not statistically significant, and 31.8% of that group saw their acne improve.
That is a trend, not a result. If you are weighing glutathione for other reasons, the NAD+ and glutathione board compares who prescribes it.
BPC-157: an animal record, and no legal route
BPC-157 has a long list of animal studies. A 2018 review from its main research group covers healing of the gut, tendons, ligaments, muscle and bone in those models [6]. None of that is a controlled trial in people, and those models are the whole of its inflammation record.
What the few human reports on BPC-157 do and do not show is covered in BPC-157 human evidence.
What this means for you
If your inflammation comes with excess weight, the strongest human data point to semaglutide. If it follows an injury, no peptide has a trial behind it yet.
For sore joints, the evidence compound by compound is in peptides for joint pain. Every option for healing and repair is gathered on the recovery goal page.